Analyst Rating Update on Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals (NYSEMKT:NAVB) : The consensus on Navidea Biopharmaceuticals (NYSEMKT:NAVB) based on 1 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Average consensus for the company shares for this week is a Strong Sell .

Navidea Biopharmaceuticals (NYSEMKT:NAVB): On Tuesdays trading session , Opening price of the stock was $0.5928 with an intraday high of $0.63. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.5601. However, the stock managed to close at $0.5601, a loss of 1.74% for the day. On the previous day, the stock had closed at $0.57. The total traded volume of the day was 866,391 shares.

In an insider trading activity, Larson Brent L, officer (EVP, CFO, Treas & Secy) of Navidea Biopharmaceuticals, Inc., unloaded 12,500 shares at an average price of $1.5 on December 1, 2015. The total amount of the transaction was worth $18,750, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimers disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinsons disease (PD) and other movement disorders.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.